Monitoring Multiple Sclerosis course and activity with TNF-alpha

Abstract

Keywords

multiple sclerosis TNF-α surrogate marker whole blood-test clinical evolution

Get full access to this article

View all access options for this article.

References

Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives . Brain 120: 865-916 .

Miller DH et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis . Ann Neurol 39: 6-16 .

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocol . An Neurol 13: 227-231 .

Peter JB , Boctor FN , Tourlelotte WW. (1991) Serum and CSF levels of IL-2, sIL-2R, TNF-a and IL-1b in chronic progressive multiple sclerosis: expected lack of clinical utility . Neurology 41: 121-123 .

Beck J et al. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78: 318-323 .

Chofflon M et al. (1992) Tumor necrosis factor a production as a possible predictor of relapse in patients with multiple sclerosis . Eur Cytokine Netw 3: 523-531 .

Sharief MK , Hentges R. (1991) Association between tumor necrosis factor -a and disease progression in patients with multiple sclerosis . N Engl J Ed 325: 467-472 .

Chofflon M et al. (1997) TNF production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis . Eur Cytokine Netw 8: 253-257 .

Rieckmann LP et al. (1994) Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis . Neurology 44: 1523-1526 .